

PLANT-BASED VACCINES, ANTIBODIES & BIOLOGICS

10-12 June 2019, University of Riga, Riga, Latvia

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR PBVAB 2019

Commercial protein drugs, which include recombinant monoclonal antibodies, subunit vaccines, immune modulators, and human enzymes, will likely exceed \$100 billion in market size within the next two years. A component of this extraordinary growth is the availability of new technologies to speed the time to market of new biologics, and to create improved versions of existing drugs. Among the new developments is the emerging use of green plants for recombinant protein production due to advantages over yeast, cultured mammalian or insect cells, or other living systems. It is becoming increasingly evident that:

- Government regulatory agencies have accepted plant production in new drug approval and licensure
- Monoclonal antibody production in plants offers rapid production advantages in comparison to mammalian cells, with at least equivalent product safety, purity and potency
- Metabolic engineering of tobacco as a host for protein production is advancing rapidly to allow highly uniform drug products, including post-translational modifications similar to those of human cells
- Plant-based manufacturing platforms hold major promise for next generation biologics (or biobetters with improved pharmacokinetic properties)
- Plant-made subunit vaccines are in the pipeline for multiple infectious diseases
- Ongoing corporate drug development at commercial scale is providing data to accurately determine the potential to reduce manufacturing cost of protein drugs under cGMP requirements using plant protein expression as the starting point

PBVAB 2019 is the eighth meeting in this important and successful series. PBVAB 2019 will offer an international forum to review the current state of research in plant protein expression systems, down-stream processing technology, the pipeline of products now in development (including vaccines, monoclonal antibodies, and human enzymes), and efforts in using these technologies in areas beyond human health (including disease prevention in animals and aquaculture).

PBVAB 2019 will aim to attract an international audience of researchers, clinicians, and representatives for academia, industry and government/regulatory/public health organizations. Representatives for the human, veterinary, plant communities with an interest in vaccinology, immunology, biotechnology issues in relation to plant-based systems will find PBVAB 2019 of value. PBVAB 2019 will seek to develop the synergy between the human and veterinary medical/immunological/plant biotechnology communities by focusing on the immunology, vaccinology, delivery, adjuvants, and efficacy of plant based proteins.

PBVAB 2019 will aim to emphasise the **take-off of the commercialisation of plant-based biologic products**, the requirement for more academic based research to respond to the question: **Where is the pipeline of products going to come from and what have we learned on the decision-making processes for that product pipeline?**

SCIENTIFIC ADVISORY PANEL

Conference Chairman: Julian Ma (*St. George's University of London, London, UK*)

Diego Orzaez (*CSIC, University of Valencia, Spain*)

George Lomonosoff (*John Innes Centre, Norwich, UK*)

Kevin Whaley (*Mapp Biopharmaceutical Inc., USA*)

Rainer Fischer (*RWTH Aachen, Germany*)

Pascal Drake (*St. George's University of London, London, UK*)

Ed Rybicki (*University of Capetown, South Africa*)

Yuri Gleba (*NOMAD Bioscience, Munich, Germany*)

Hugh Haydon (*Kentucky BioProcessing, Owensboro, Kentucky, USA*)

Qiang 'Shawn' Chen (*Arizona State University, Tempe, Arizona, USA*)

Marc-Andre D'Acoust (*Medicago Inc., Quebec, Canada*)

Ann Depicker (*University of Ghent, Ghent, Belgium*)

Yoseph Shaaltiel (*Protalix Biotherapeutics, Carmiel, Israel*)

Takeshi Matsumura (*AIST, Japan*)

Marcos da Silva Freire (*Bio-Manguinhos/Fiocruz, Brazil*)

Andres Wigdorovitz (*INTA, Buenos Aires, Argentina*)

Sun Lee (*NEXGEN Biotechnologies Inc., Seoul, South Korea*)

Victor Klimyuk (*ICON Genetics GmbH, Halle, Germany*)

Robert Erwin (*iBio Inc., Newark, Delaware, USA*)

Andreas Schaaf (*Greenovation Biotech, Freiburg, Germany*)

CONFERENCE SESSIONS/TOPICS

Main Sessions: Challenges to Commercialisation · Product Pipelines · Vaccines · Antibodies · Adjuvants · Biologics
Expression Systems · Pre-clinical & Clinical Evaluations · Regulatory & Socio-ethical Issues

The PBVAB 2019 conference will focus on the following main topics: Global need for vaccines and antibodies that can address large, cost-sensitive markets · Plant-based protein expression systems · Molecular pharming issues · Plant viral vector expression systems · Plant-derived antigens & adjuvants · Production and scale-up · Plant-derived antibodies with infectious agent targets/new targets · Purification and GMP manufacture · Regulatory control · Biofuels · Containment strategies (physical/genetic) · Delivery systems · Biofortification · Preventing pathogen transmission across mucosal surfaces · Downstream processing issues · Clinical trials · Biosafety/regulatory/public health issues

Whilst this list is not exhaustive it does give an indication of the main focus of PBVAB 2019 and the areas where abstract submissions for both oral and poster presentation are being encouraged by the Scientific Advisory Panel.



Abstract Submissions

The PBVAB 2019 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during PBVAB 2019. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (PBVAB 2019 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

PBVAB MEETINGS ATTRACT A LARGE NUMBER OF ABSTRACT SUBMISSIONS FOR BOTH ORAL AND POSTER PRESENTATION – AUTHORS SHOULD NOTE THAT ONLY A SELECTION OF INTENDED ORAL ABSTRACTS WILL BE SELECTED FOR INCLUSION IN THE ORAL PROGRAMME BASED PURELY ON MERIT, CONTENT AND RELEVANCE TO THE AIMS AND SCOPE OF THE PBVAB 2019 SCIENTIFIC PROGRAMME – THE SCIENTIFIC ADVISORY PANEL URGE AUTHORS TO INCLUDE SUFFICIENT DETAIL WITHIN ABSTRACTS TO ENHANCE THE REVIEW AND SELECTION PROCESS.

Closing date for submissions intended for oral presentation: **Friday 18th January 2019**. Authors will be informed of the status of their contribution(s) in February 2019. Closing date for submissions intended for poster presentation: **Friday 17th May 2019**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to PBVAB 2019. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at PBVAB 2019. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on PBVAB 2019
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- My organisation is interested in sponsoring PBVAB 2019 Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- HUMAN ANTIBODIES & HYBRIDOMAS** – 22-24 October 2018, Riga, Latvia
- MUCOSAL VACCINES ADJUVANTS & DELIVERY** – 12-14 November 2018, Lausanne, Switzerland
- INFLUENZA VACCINES FOR THE WORLD** – 2-4 April 2019, Edinburgh, Scotland, UK
- MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS** – 9-11 September, Bern, Switzerland
- VACCINES FOR ENTERIC DISEASES** – 16-18 October 2019, Lausanne, Switzerland

PLEASE RETURN THIS FORM TO:


JOHN HERRIOT, PBVAB 2019, MEETINGS MANAGEMENT

Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com

Website: www.meetingsmanagement.com/pbvab_2019

The International Society for
Plant Molecular Farming



**International Society
for Plant Molecular Farming**

Details are available at:
www.societyformolecularfarming.org

For membership enquiries please contact: Professor Julian Ma, Hotung Chair of Molecular Immunology, Joint Director, Institute for Infection and Immunity St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom
Tel: 020 8725 5818 Fax: 020 8725 3487 E-mail: jma@sgul.ac.uk